Abstract Title: currently loading...

information currently loading...

Loading ... please wait
timer Loading ... please wait


10:00 - 11:30 | 06 September | Room: Speakers' Corner.

Back to Previous

10:00Influence of mitochondrial haplogroups in response to ranibizumab therapy in neovascular age-related macular degeneration.
F. Ascaso Spain
10:05Anti-VEGF persistence and switching in nAMD: real world analysis from a Canadian claims database
P. Yoganathan Canada
10:15Bringing clinical trials results to real life in nAMD. Results of an advanced intravitreal treatment setting in a public hospital in Spain
D. Rodriguez-Feijoo Spain
10:20Changes in macular pigment optical density with age in healthy and in patients with dry age-related macular degeneration: a cross sectional study
I. Chang South Korea
10:25Drug utilization and associated visual acuity in patients treated with anti-VEGFs for neovascular age-related macular degeneration (nAMD) in the UK
A. Sagkriotis Switzerland
10:30Effects of intravitreal connective tissue growth factor neutralizing antibody on the CNV-associated subretinal fibrosis
N. Daftarian Iran
10:35Eighteen month outcomes of treat and extend regime for AMD with intravitreal aflibercept in clinical setting as compared to results of VIEW1 and VIEW 2.
E. Gokhale UK
10:40Four-year outcome of Aflibercept therapy for neovascular age-related macular degeneration
Y. Gayadine-Harricham France
10:45Geographic atrophy (GA) secondary to neovascular age related macular degeneration (nAMD): Online medical education significantly improves ophthalmologists’ knowledge, competence and confidence
S. Trier UK
10:50National survey on the management and information practices of patients with wet AMD
E. Fourmaux France
10:55Optical coherence tomography – Angiography as a tool for guiding treatment interval between anti-VEGF injections in neovascular age related macular degeneration.
R. Rasheed UK
11:00Optical coherence tomography (OCT) findings in lacquer crack hemorrhage (LCH).
K. Chia Singapore
11:05Persistence to intravitreal aflibercept therapy in patients with wet age-related macular degeneration engaged with the smartsight support program
A. Chang Australia
11:10Polyp evolution over 24 months among patients with polypoidal choroidal vasculopathy
C. Tan Singapore
11:15Polypoidal choroidal vasculopathy in pachychoroid: aflibercept and PDT combined therapy.
M. Vadalà Italy
11:20Swept-source optical coherence tomography (ssOCT) imaging in vitreoretinal interface disorders (VRID) and their role in intravitreal treatment response in wet age-related macular degeneration (AMD)
M. Garcia-Mendieta Spain
Back to Previous

Sign up to EURETINA

© EURETINA All rights reserved